Medical World News® Deep Dive: Making Cell and Gene Therapy Practical

Video

Josh Ludwig detailed to CancerNetwork® how ScaleReady can help make cell and gene therapy widely practical and viable for patients with cancer.

In a recent episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Josh Ludwig, the global director of commercial operations at ScaleReady, about how a joint venture launched in January 2021 between Bio-Techne, Fresenius Kabi, and Wilson Wolf is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.

Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
6371178759112
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Related Content
Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care

Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care

Tim Cortese
April 24th 2025
Article

Polypharmacy, medication list errors, and drug-drug interactions were all observed in patients with cancer receiving oral anticancer drugs.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic

Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic

Tim Cortese
April 22nd 2025
Article

An annual report on the status of cancer showed that, from 2018 to 2022, the cancer death rate fell for every race and ethnicity.

Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress

Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress

Tim Cortese
April 20th 2025
Article

Patients with a cancer signal detected via multicancer early detection test demonstrated similar results to those who did not in the PATHFINDER cohort study.